The FDA on Tuesday approved etuvetidigene autotemcel (Waskyra) as the first cell-based gene therapy for patients 6 months and ...
Aradigm Health, a new benefits platform aimed at easing the financial sting of coverage for cell and gene therapies, has ...
The FDA has issued its stamp of approval to a new, cell-based option to treat Wiskott-Aldrich syndrome (WAS), marking the ...
Pharmaceutical Technology on MSN
Cell and gene therapy investment strategy pivots as funding dries up
Later-stage financing deals for cell and gene therapy companies reflects a broader derisking trend in the pharma industry.
Backed by Italy-based Fondazione Telethon ETS, Waskyra, for Wiskott-Aldrich syndrome, is the first gene therapy from a ...
A cutting-edge base-edited CAR T-cell therapy is opening a revolutionary new frontier for patients battling aggressive T-cell ...
FDA approves 1st gene therapy for Wiskott-Aldrich syndrome, offering a new treatment for patients lacking matched stem cell donors.
The chief medical officer of Genetix Biotherapeutics, formerly known as Bluebird bio, discusses timelines and operational ...
Key Highlights Motixafortide effectively mobilized sufficient hematopoietic stem cells (HSCs) in patients with sickle cell disease enabling accelerated access to gene therapies 90% (9 of 10) of ...
Dec 6 (Reuters) - Vertex Pharmaceuticals said on Saturday its gene therapy helped children aged between 5 and 11 years with ...
4d
CT joins national push to open access to million-dollar sickle cell gene therapies through Medicaid
About 100,000 people in the U.S. have sickle cell disease, a condition that primarily affects people of color, the CDC says.
A small group of patients with an otherwise incurable form of T‑cell leukemia have seen their cancer driven into remission by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback